CYTOF supply chain intelligence for Altamira Therapeutics Ltd.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Altamira Therapeutics Ltd. (CYTOF) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BPTH | Bio-Path Holdings, Inc. | 72% | nclude Acuitas Therapeutics Inc., Andros Pharmaceuticals Co., Ltd., Aro Biotherapeutics, Avidity Biosciences, Inc., Bio-Path Holdings, Inc., Chimeron Bio Inc., Dicerna Pharmaceuticals, Inc., Duet Bio… |
| BPTH | Bio-Path Holdings, Inc. | 72% | Reciprocal relationship from BPTH graph: Reciprocal relationship from CYTOF graph: Reciprocal relationship from BPTH graph: Reciprocal relationship from CYTOF graph: nclude Acuitas Therapeutics Inc.,… |
| HTGC | Hercules Capital, Inc. | 72% | Reciprocal relationship from HTGC graph: Reciprocal relationship from CYTOF graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from CYTOF graph: 155,870 58,839 7,861 222,570 As o… |
| HTGC | Hercules Capital, Inc. | 72% | 155,870 58,839 7,861 222,570 As of December 31, 2016 99,170 49,996 220,128 369,294 As of December 31, 2016, and 2015 no items of property and equipment were pledged. Refer to note 24 for security pro… |
| JNJ | Johnson & Johnson | 72% | nclude Acuitas Therapeutics Inc., Andros Pharmaceuticals Co., Ltd., Aro Biotherapeutics, Avidity Biosciences, Inc., Bio-Path Holdings, Inc., Chimeron Bio Inc., Dicerna Pharmaceuticals, Inc., Duet Bio… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from CYTOF graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from CYTOF graph: nclude Acuitas Therapeutics Inc., A… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from CYTOF graph: PI of Keyzilen ® , Sonsuvi ® , AM-125 and AM-201. We are reliant upon single source third-party contract manufactur… |
| ORANY | ORANY | 72% | PI of Keyzilen ® , Sonsuvi ® , AM-125 and AM-201. We are reliant upon single source third-party contract manufacturing organizations to manufacture and supply the drug substance and drug product and … |
| RNAM | RNAM | 72% | nclude Acuitas Therapeutics Inc., Andros Pharmaceuticals Co., Ltd., Aro Biotherapeutics, Avidity Biosciences, Inc., Bio-Path Holdings, Inc., Chimeron Bio Inc., Dicerna Pharmaceuticals, Inc., Duet Bio… |
| RNAM | RNAM | 72% | Reciprocal relationship from RNAM graph: Reciprocal relationship from CYTOF graph: nclude Acuitas Therapeutics Inc., Andros Pharmaceuticals Co., Ltd., Aro Biotherapeutics, Avidity Biosciences, Inc., … |
| RNAZ | TransCode Therapeutics, Inc. | 72% | nclude Acuitas Therapeutics Inc., Andros Pharmaceuticals Co., Ltd., Aro Biotherapeutics, Avidity Biosciences, Inc., Bio-Path Holdings, Inc., Chimeron Bio Inc., Dicerna Pharmaceuticals, Inc., Duet Bio… |
| RNAZ | TransCode Therapeutics, Inc. | 72% | Reciprocal relationship from RNAZ graph: Reciprocal relationship from CYTOF graph: nclude Acuitas Therapeutics Inc., Andros Pharmaceuticals Co., Ltd., Aro Biotherapeutics, Avidity Biosciences, Inc., … |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| HEQET-THERAPEUTICS | HEQET-THERAPEUTICS | 92% | In July 2023, we announced our first collaboration with a biopharmaceutical company to develop and evaluate our xPhore delivery platform with a specific RNA molecule developed by the client (Heqet Th… |
| UNIVERCELLS | UNIVERCELLS | 92% | This was followed in 2024 by two further collaborations (March: Univercells, mRNA vaccines; December: undisclosed partner, radiopharmaceuticals). |
| ALKS | Alkermes plc | 72% | Reciprocal relationship from ALKS graph: Reciprocal relationship from CYTOF graph: Reciprocal relationship from ALKS graph: Reciprocal relationship from CYTOF graph: payors, including private insurer… |
| ALKS | Alkermes plc | 72% | payors, including private insurers, and some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guida… |
| BPTH | Bio-Path Holdings, Inc. | 72% | nclude Acuitas Therapeutics Inc., Andros Pharmaceuticals Co., Ltd., Aro Biotherapeutics, Avidity Biosciences, Inc., Bio-Path Holdings, Inc., Chimeron Bio Inc., Dicerna Pharmaceuticals, Inc., Duet Bio… |
| BPTH | Bio-Path Holdings, Inc. | 72% | Reciprocal relationship from BPTH graph: Reciprocal relationship from CYTOF graph: Reciprocal relationship from BPTH graph: Reciprocal relationship from CYTOF graph: nclude Acuitas Therapeutics Inc.,… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from CYTOF graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from CYTOF graph: nclude Acuitas Therapeutics Inc., A… |
| JNJ | Johnson & Johnson | 72% | nclude Acuitas Therapeutics Inc., Andros Pharmaceuticals Co., Ltd., Aro Biotherapeutics, Avidity Biosciences, Inc., Bio-Path Holdings, Inc., Chimeron Bio Inc., Dicerna Pharmaceuticals, Inc., Duet Bio… |
| RNAM | RNAM | 72% | Reciprocal relationship from RNAM graph: Reciprocal relationship from CYTOF graph: nclude Acuitas Therapeutics Inc., Andros Pharmaceuticals Co., Ltd., Aro Biotherapeutics, Avidity Biosciences, Inc., … |
| RNAM | RNAM | 72% | nclude Acuitas Therapeutics Inc., Andros Pharmaceuticals Co., Ltd., Aro Biotherapeutics, Avidity Biosciences, Inc., Bio-Path Holdings, Inc., Chimeron Bio Inc., Dicerna Pharmaceuticals, Inc., Duet Bio… |
| RNAZ | TransCode Therapeutics, Inc. | 72% | Reciprocal relationship from RNAZ graph: Reciprocal relationship from CYTOF graph: Reciprocal relationship from RNAZ graph: Reciprocal relationship from CYTOF graph: nclude Acuitas Therapeutics Inc.,… |
| RNAZ | TransCode Therapeutics, Inc. | 72% | nclude Acuitas Therapeutics Inc., Andros Pharmaceuticals Co., Ltd., Aro Biotherapeutics, Avidity Biosciences, Inc., Bio-Path Holdings, Inc., Chimeron Bio Inc., Dicerna Pharmaceuticals, Inc., Duet Bio… |
| SNYNF | Sanofi | 72% | ), as well as our early- to late-stage clinical development programs in tinnitus and hearing loss. We started our activities in RNA delivery in 2021 through the acquisition of Trasir Therapeutics Inc… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from CYTOF graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CYTOF graph: Reciprocal relationship from SN… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| CYTOF-DEBT-9004 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2020-12-01. |
| CYTOF-DEBT | Debt stack $523,920 | 90% | Market cache reports total debt of $523,920. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BNR | Burning Rock Biotech Limited | 100.00 | 2 | |
| CSTE | Caesarstone Ltd. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| ALKS | Alkermes plc | 100.00 | 1 | ['customer'] |
| BPTH | Bio-Path Holdings, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 |